A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...
Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer ...
New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective A new study demonstrates the ability of a multi-biomarker ...
Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback